AFX 2101

Our lead drug candidate from a novel series of potent anti-inflammatory small molecules that inhibit CCL2/CCR2, a key pro-inflammatory pathway. The CCL2/CCR2 pathway is responsible for the movement of inflammatory cells to sites of inflammation such as the skin in patients with atopic dermatitis, as well as many other diseases.